Economic Observation Network In the past three months, China National Pharmaceutical Group Corporation (Sinopharm) has successively listed and sold multiple subsidiaries. The four medical laboratory units planned to be sold this time have poor profitability performance in the first five months of 2026.

Progress of asset disposal:
On July 9th, four medical testing laboratories under the company's subsidiary, Sinopharm Genomics (Changzhou, Wuhan, Yantai, etc.), were listed for sale on the Beijing Property Rights Exchange. These companies were generally in a loss or low profit state in the first five months of 2026 This is not an isolated incident. In the past three months, at least 7 companies under China National Pharmaceutical Group have been listed, which is a continuation of the company's strategy of focusing on its main business and optimizing its asset structure 。

The above content is based on publicly available information and does not constitute investment advice.